Oral Drug Wins FDA Approval for Chronic Hives

(MedPage Today) — The FDA approved oral remibrutinib (Rhapsido) as a second-line treatment for chronic spontaneous urticaria (CSU), or chronic hives, Novartis announced on Tuesday.
Indicated for adults with stubborn symptoms despite the use of…